An Evaluation of a Measure of the Proportion of the Treatment Effect Explained by a Surrogate Marker
- 22 December 1998
- journal article
- Published by Elsevier in Controlled Clinical Trials
- Vol. 19 (6) , 555-568
- https://doi.org/10.1016/s0197-2456(98)00039-7
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKERStatistics in Medicine, 1997
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Viral Load and Response to Treatment of HIVNew England Journal of Medicine, 1996
- Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDSNew England Journal of Medicine, 1996
- A Stochastic Model for Analysis of Longitudinal AIDS DataJournal of the American Statistical Association, 1994
- Evaluating the role of CD4‐lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trialsStatistics in Medicine, 1993
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992
- Applications of a computer simulation model of the natural history of CD4 T-cell number in HIV-infected individualsAIDS, 1991
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989